Review Article

The human hypothalamus in mood disorders: The HPA axis in the center

Ai-Min Bao\textsuperscript{a,⁎}, Dick F. Swaab\textsuperscript{a,b}

\textsuperscript{a} Department of Neurobiology and Department of Neurology of the Second Affiliated Hospital, Institute of neuroscience, NHC and CAMS key laboratory of Medical Neurobiology, Zhejiang University School of Medicine, Hangzhou, China
\textsuperscript{b} Netherlands Institute for Neuroscience, An Institute of the Royal Netherlands Academy of Arts and Sciences, Amsterdam, the Netherlands

**ARTICLE INFO**

**Keywords:**
- The hypothalamo-pituitary-adrenal axis
- Glutamate
- GABA
- Neuropeptide
- Sex differences

**ABSTRACT**

There are no specific structural neuropathological hallmarks found in the brain of mood disorders. Instead, there are molecular, functional and structural alterations reported in many brain areas. The neurodevelopmental underpinning indicated the presence of various genetic and developmental risk factors. The effect of genetic polymorphisms and developmental sequelae, some of which may start in the womb, result in functional changes in a network mediated by neurotransmitters and neuropeptides, which make the emotion- and stress-related brain systems more vulnerable to stressful events. This network of stress-related neurocircuits consists of, for instance, brainstem nuclei, the amygdala, habenula, prefrontal cortex and hypothalamus. Various nuclei of the hypothalamus form indeed one of the crucial hubs in this network. This structure concerns not only the hypothalamo-pituitary-adrenal (HPA) axis that integrate the neuro-endocrine-immune responses to stress, but also other hypothalamic nuclei and systems that play a key role in the symptoms of depression. The present review will focus on the changes in the human hypothalamus in depression, with the HPA axis in the center. We will discuss the inordinate network of neurotransmitters and neuropeptides involved, with the hope to find the most vulnerable neurobiological systems and the possible development of tailor-made treatments for mood disorders in the future.

**Introduction**

Structural and functional brain alterations have been found in mood disorders in a network of stress-related systems, such as the brainstem nuclei, the locus coeruleus (LC) and raphe nuclei (Bao et al., 2012), which are the first relay stations for many physiological stressors. The amygdala processes fear and anxiety responses (Wang et al., 2014); the hippocampus mediates learning and memory and encodes the immediate and executive functions but also regulates the stress axis (see below) (Aihara et al., 2007; Qi et al., 2013, 2015; Qi et al., 2017; Zhao et al., 2016; Lu et al., 2017; Price and Drevets, 2012). The lateral habenula is a relatively new structure known to be involved in depression (Yang et al., 2018). This review deals with one of the important hubs in this network, which is involved in the symptoms of depression, i.e. a number of human hypothalamic neuropeptide-containing nuclei, from which recent evidence of their alterations in depression is accumulating. It should be noted that not all hypothalamic nuclei are discussed, partly because of a lack of information, such as for the anterior part of the hypothalamus with the exception of the suprachiasmatic nucleus (SCN, see below); and partly because of no important alterations were observed in depression, such as in the histaminergic tuberomammillary nucleus in the posterior hypothalamus (Shan et al., 2013). In the present review, we put the hypothalamo-pituitary-adrenal (HPA) axis in the center, because of its intensive interaction with other stress-related neuropeptide-, amine- and amino acid systems in depression. It should be noted though, that a causal role of the human HPA axis in general, and of corticotropin-releasing hormone (CRH) in particular, in mood disorders, is still in discussion (Spierling and Zorrilla, 2017). Changes in molecular neuropathology in the hypothalamus, i.e. the neurotransmitter and neuromodulator alterations, are due to a multitude of different genetic and developmental causes, which lead to changes in the stress- and reward-related network (Lucassen et al., 2014; Menezes et al., 2018). These changes may in different ways cause individuals to be at risk for a mood disorder. In case of the occurrence of stressful environmental events, they may over-react to these events and develop a depression.

---

\* Corresponding author.

E-mail address: baoaimin@zju.edu.cn (A.-M. Bao).

https://doi.org/10.1016/j.ibror.2018.11.008
Received 14 November 2017; Accepted 28 November 2018
2451-8301/ © 2018 The Authors. Published by Elsevier Ltd on behalf of International Brain Research Organization. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
The HPA axis

The first time the HPA axis became the focus of depression studies was by the correlation found by Hans Selye in the 1930s between the dysregulation of the stress response and mood disorders, especially major depression (Selye, 1998). It has since then become well accepted that, although the stress response is necessary to maintain homeostasis, long-term activation of the stress system may bring hazardous or even lethal effects, and increases the risk of depression (Selye, 1998). Abnormalities in the ‘stress system’ have been documented in mood disorders in various stress related systems. The neural network that encodes and evaluates the stressful event comprises e.g. the HPA axis, the arginine vasopressin (AVP) systems, and the noradrenergic system, which are the very same brain circuits that, when they are hyperactive due to a combination of a genetic background, developmental sequelae and life events, underlies negative emotions and moods. Major depressive disorder (MDD) thus arises from the interaction of vulnerability genes and developmental and environmental factors (Lucassen et al., 2014). Prenatal environmental stressors such as placental insufficiency, food shortage or nicotine exposure due to smoking of the pregnant mother may sensitize the child for developing depression in later life (Clark, 1998; Swaab, 2004). Psychosocial stress such as early maternal separation, child abuse or neglect may also program the HPA axis by epigenetic means permanently into a higher activity, while death or loss of a spouse, or personal injury or illness form risk factors that may trigger the early episodes of depression (Lucassen et al., 2014; Bao et al., 2012).

When activated, the HPA axis stimulates the synthesis and release of cortisol, which normally has broad biological effects throughout the body that are adaptive but can become damaging when chronically elevated. Chronic elevation of cortisol secretion in some depressive subtypes is thought to be responsible for mitochondrial dysfunction, neuropathological changes, elevated temperature, osteoporosis and aging, and other medical causes of individuals with mood disorders (Gold et al., 2002). Cortisol exerts negative feedback at the pituitary and the hypothalamic level (Wang et al., 2008) and acts on other brain areas such as the PFC and the hippocampus via two types of receptors, i.e. the mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR), to shut down the stress responses after the threat has passed (Aihara et al., 2007; Qi et al., 2013). The termination of the stress response is as important as its initiation, since superfluous cortisol can cause broad endocrine dysregulation (Lucassen et al., 2014). Moreover, the high proportion of depressed patients in cases of Cushing’s disease and during the treatment with high dosage of synthetic corticosteroids point to a possible causal role of glucocorticoids in a subset of mood disorders (Bao et al., 2012). However, it should be noted here that certainly not all studies on peripheral blood samples show elevated levels of cortisol in MDD patients (see for instance Sigurdsson et al., 2014). Several points should be taken into consideration here. In the first place, morning salivary and serum cortisol levels were reported to be reduced in depression (Strickland et al., 2002), while such observations may well be related to the alterations in the circadian rhythms in mood disorder patients (Zhou et al., 2001; Wu et al., 2017) rather than pointing to the lack of activation of the HPA axis. Secondly, if cortisol is not elevated in mood disorder patients, it does not necessarily mean that the HPA axis is not activated. The classic CRH neurons in the paraventricular nucleus (PVN) project to the portal blood vessels of the median eminence and regulate adrenocorticotropic hormone (ACTH) production in the pituitary. However, there are also CRH neurons that are activated in the stress response and depressive disorders, that project to different brain areas and may induce at least a part of the mood disorder symptoms. It is important, in this respect, that central administration of CRH in the brain can mimic the signs and symptoms of major depression (Holsboer et al., 1992). Activity changes in a subgroup of centrally projecting CRH neurons may not be directly monitored by measuring hormonal alterations in the periphery, but might be reflected better in CRH cerebrospinal fluid (CSF) levels. Thirdly, enhanced sensitivity for cortisol may also be a reason for low peripheral cortisol levels, while CRH expression is high, as shown in posttraumatic stress disorder (PTSD), a disorder with an enhanced risk for mood disorder (Morris et al., 2012). A meta-analysis showed that plasma or serum cortisol levels in PTSD did not differ from controls. When controls that were not exposed to trauma were compared to PTSD patients, the cortisol levels in the PTSD group were even lower in the latter (Meewisse et al., 2007). The hypersensitivity of the cortisol feedback is at least partly due to single nuclear polymorphisms (SNPs) in the GR gene, FKBP5 gene or CRH receptor (CRH-R)-1 gene (Castro-Vale et al., 2016). The genetic basis of the hypersensitivity means that this will be a general phenomenon in the brain of patients carrying such a SNP. Finally, an opposite case of low levels of CRH should also be mentioned, i.e. the atypical depression, which shows high levels of corticosteroids, accompanied by low levels of CRH (Gold et al., 2002; Erkut et al., 1998).

Concluding, during development the HPA axis may be permanently activated by genetic or environmental factors and make people vulnerable to environmental stress that can further activate the HPA axis on different levels. The activated HPA axis may affect mood by the central projections of CRH and/or enhanced circulating levels of corticosteroids, while SNPs on the different levels of the HPA axis may be the basis of variability in sensitivity of the brain for cortisol.

Interaction between the HPA axis, neurotransmitters and neuromodulators

Monoamines

The HPA axis is innervated and regulated by a large number of neurotransmitters and neuropeptides that show alterations in mood disorders. Over the past four decades, the focus on the brain monoaminergic systems, which contain serotonin ( = 5-hydroxytryptamine, 5-HT), noradrenalin (NA) and dopamine (DA), has contributed significantly to our knowledge of the pathophysiology and treatment of depression. In addition, the focus on amines has contributed to the development of a growing number of antidepressants, including the tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors and monoamine receptor antagonists (Hirschfeld, 2012).

Stress activates not only the HPA axis, but also 5-HT neuronal activity and increases the extracellular 5-HT levels in the dorsal raphe nucleus (Waseles et al., 2011). A large body of evidence shows a remarkable effect of an altered 5-HT system on the activity of the HPA axis involving the 5-HT (serotonin) 2C receptor. In particular, acute administration of 5-HT receptor ligands increased the plasma levels of ACTH and cortisol in both animals and humans (Heisler et al., 2007). A light and electron microscopic immunocytochemical study in the rat brain demonstrated that serotonin-containing terminals formed axo-dendritic and axo-somatic synapses with CRH-immunoreactive (ir) neurons in the hypothalamic PVN, which indicates that the central serotonergic system can influence the function of the HPA axis via a direct action upon the CRH synthesizing neurons (Liposits et al., 1987). Indeed, 5-HT1A and 5-HT2A receptors with a high degree of co-localization in the CRH neurons were found in the PVN, while microinjection of 5-HT1A agonist (8 – OH-DPAT) into the PVN triggered ACTH secretion through local 5-HT1A receptor activation (Osei-Owusu et al., 2005; Zhang et al., 2004).

It should be noted, however, that antidepressants aiming at the amimergic systems appear to be effective only in 40–60% of the patients. Moreover, there is a huge discrepancy between the pharmacological/biochemical function of these antidepressants (a few minutes) and their clinical mood-altering responses (10–15 days or longer) (Leonard, 2007), which is a serious problem in understanding what mechanisms these antidepressants modify in their effects to relieve depression. It is now also clear that there is no simple direct relationship between changes in the amimergic systems and the occurrence of
depression (Ruhe et al., 2007).

Communication between NA and the HPA axis has also been extensively reported during stress responses and in depression (Gold, 2015). Electrical stimulation of the ventral noradrenergic ascending bundle, the principal pathway of NA fibers to the PVN, was found to increase CRH release to the portal system, an effect that could be blocked by an α1-adrenergic antagonist. Norepinephrine (NE = NA) microinjection into the PVN of conscious rats induces a rapid increase of CRH heteronuclear RNA expression in the parvocellular division of the PVN. In addition, immobilization stress has been observed not only to enhance NE release, reuptake, metabolism, and synthesis in the PVN and the medial PFC, but also to trigger transcriptional activation of the genes encoding catecholamine biosynthetic enzymes in the LC, a target for CRH neurons. Moreover, local CRH infusion showed that CRH serves as an excitatory neurotransmitter in the LC, and suggest that its actions on LC neurons are translated into enhanced NE release, which has an impact on cortical targets. Furthermore, NA-receptor sensitivity is altered by the circulating level of glucocorticoids (Bao et al., 2012). Under normal circumstances, noradrenergic systems can influence the magnitude of the HPA axis response to stress. However, in MDD subjects the HPA axis activation appears autonomous of noradrenergic influence (Young et al., 2005).

DA, too, plays a role in the stress response and is dysregulated in mood disorders. Stress exposure and elevated levels of glucocorticoids enhance DA release and influence the activity or synthesis of tyrosine hydroxylase in the nucleus accumbens (Belujon and Grace, 2017). At the anatomical level, a large number of DA receptor D-1 subtype positive neurons exist in both magnocellular and parvocellular parts of the hypothalamic PVN, and there is evidence that corticosterone may regulate the expression of D-1 while DA via D-1 receptors may regulate the amount of circulating corticosterone (Czyrak et al., 2003). Human brain imaging studies have provided further evidence that stress-related increases in cortisol are associated with DA accumulation in the ventral striatum (Oswald et al., 2005; Pfeifer et al., 2004). DA was found to be produced not only in the substantia nigra and ventral tegmentum, but also in the neurons of the PVN and supraoptic nucleus (SON) (Panayotacopoulou et al., 2005; Dudas et al., 2010), although the role of DA in these nuclei in physiology and mood disorders is not clear at present. It seems that not only glucocorticoids, acting through GRs, may regulate the function of the dopaminergic systems, but that DA, especially via D-1 receptor, found in the hypothalamic PVN, SON, and SCN (Fremeau et al., 1991), may participate in a wide variety of hypothalamic functions involved in the integration of endocrine, autonomic, and behavioral processes. Expression of D-1 receptors in the SCN, the biological clock of the hypothalamus, suggests that D-1 receptors may influence the regulation of circadian rhythms that are disturbed in depression (Czyrak et al., 2000, 2003; Wu et al., 2017).

Concluding, the HPA axis is innervated by the serotonergic, noradrenergic and dopaminergic systems, while during the stress response the interplay between the HPA axis and these aminergic systems forms a concerted action.

Glutamate and GABA

Amino acid neurotransmitters are also presumed to play an important role in the pathogenesis of depression. Glutamate and GABA are, respectively, the principal excitatory and inhibitory neurotransmitters in the central nervous system (Lener et al., 2017). Unlike the monoamine transmitters that occupy about 5% of the total synapses in the brain, glutamate and GABA are thought to account for at least 50% of the synapses (Leonard, 2007). In addition, excitatory glutamatergic and inhibitory GABAergic synaptic inputs have been identified on hypothalamic CRH-expressing neurons. Glutamate administration in the PVN of rat causes a rise in ACTH and corticosterone serum levels by promoting CRH secretion (Herman et al., 2004), while glutamate modulators have shown therapeutic effects in depression (Henter et al., 2018). Moreover, a reduced GABAergic tone of the parvocellular neurons in the PVN, indicating hyperactivity of this nucleus, was observed during chronic stress (Gao et al., 2017). This implies a diminished inhibition to CRH-producing cells that may lead to an activation of the HPA axis (Verkuyl et al., 2004). A 43% significant reduction of the density of glutamic acid decarboxylase (GAD)65/67-ir was found in the hypothalamic PVN of MDD patients (Gao et al., 2012). In fact, it is well accepted now that there are two major inhibitory mechanisms which serve to constrain the basal and stress-induced activity of the HPA axis: 1) the corticosteroid feedback and 2) the inhibition of the PVN by the neurotransmitter GABA, the two of which work together and influence each other (Gao et al., 2013; Schmidt et al., 2005).

Neuropeptides

There is strong evidence implying that neuropeptides, e.g. CRH and AVP and oxytocin (OXT), do not only play an important role in the integration of endocrine, autonomic, and higher brain functions, but also contribute to the symptoms of depression (Bao et al., 2012).

CRH

The number of CRH neurons, the number of CRH neurons co-expressing AVP, and the amount of CRH-mRNA in the PVN are significantly increased in the postmortem brain of subjects with a long history of mood disorders, independent of whether they die during a depressive state or not (Bao et al., 2005; Raadsheer et al., 1994a, 1995; Wang et al., 2008). A recent study showed that the CRH plasma levels in MDD patients are significantly higher than those in healthy controls (Lu et al., 2018). In addition, epigenetic DNA methylations of the CRH gene were found to be risk factors for psychiatric illness in adolescents (Jokinen et al., 2018). Intracranial injection of CRH in rodents induces depression-like changes including decreased food intake, decreased sexual activity, disturbed sleep and motor behavior, and increased anxiety (Holsboer, 2001).

Parvocellular PVN neurons secrete both, CRH and AVP, as neuropeptides in the median eminence into the portal capillaries, that transport them to the anterior lobe of the pituitary. AVP strongly potentiates the ACTH-releasing activity and, eventually, the production of corticosteroids from the adrenal gland (Engelmann et al., 2004). Thus, there is a close interaction between CRH, AVP and HPA axis activity. During postnatal development, CRH controls the activity of the HPA axis and mediates the effects of early disturbances such as maternal deprivation through the CRH-R1 (Schmidt et al., 2006). In addition, SNPs in the CRH-R1 and CRH-R2 genes were found to be associated with increased susceptibility to MDD, indicating a possible primary role for the CRH-R at least in some cases of depression (Liu et al., 2006b; Ishiibori et al., 2012).

GR-mRNA concentration and glucocorticoid binding activity were increased in brain tissues of animals chronically treated with antidepressants. The time course of the antidepressant effects on GRs coincides with their long-term actions on the HPA activity and follows closely that of clinical improvement of depression (Barden, 1996). In addition, decreased methylation of the GR gene promoter was observed in leukocytes of patients with anxiety and depressive disorder (Tyrrka et al., 2016). The clinical observation that patients with treatment-resistant depression noticed a significant improvement in mood after receiving dexamethasone while remaining on their antidepressant (sertraline or fluoxetine) further supports the concept that hyperactive CRH neurons play a causal role in the symptomatology of depression (Dinan et al., 1997). Moreover, the CRH concentrations in CSF in healthy volunteers and depressed patients decrease due to prolonged treatment with antidepressant drugs (Heuser et al., 1998), although it should be noted that CSF-CRH can also be derived from other brain areas, such as the thalamus (Bao et al., 2005; Hsu et al., 2001).

Lastly, in depressed patients significantly increased CRH-mRNA levels in the PVN were found to be accompanied by a significantly increased expression of genes involved in the activation of CRH neurons, such as CRH-R1, MR, estrogen receptor-alpha (ER-α), and AVP receptor
(AVPR) subunit AVPR1a, together with a significantly decreased expression of genes involved in the inhibition of CRH neurons, such as the androgen receptor (AR) mRNA (Wang et al., 2008). These findings obtained by laser microdissection of the PVN further raise the possibility that a disturbed receptor balance in the PVN may contribute to the activation of the HPA axis in depression. Together, the arguments mentioned above support the CRH-hypothesis of depression (Holsboer, 1988): hyperactivity of CRH neurons, and thus of the HPA axis, is of crucial importance for the induction of the symptoms of depression, at least in a subgroup of patients.

AVP

Besides the role of AVP in the regulation of osmolality, blood pressure, temperature, and corticosteroid secretion, the centrally-projecting vasopressinergic fibers are involved in the stress response, cognition, social attachment and emotionality. Intrasal ASL AVP differentially affects social communication in men and women (Caldwell and Albers, 2016). The human brain contains AVPR in many areas (Freeman et al., 2017; Loup et al., 1991). There are at least 4 different vasopressinergic systems intimately involved in the symptoms of depression (for reviews see (Swaab, 2003, 2004)). First, AVP is produced as a neurohormone by the magnocellular neurons of the hypothalamic SON and PVN, whose axons run to the neurohypophysis where it is released into the general circulation. Circulating AVP has an influence on the anterior pituitary and high levels of circulating AVP also affect mood. In the second place, parvocellular neurons of the PVN secrete CRH and AVP also as neurohormones from their axons in the median eminence into the portal capillaries that transport them to the anterior lobe of the pituitary. AVP strongly potentiates ACTH-releasing activity (Engelmann et al., 2004). Third, additional vasopressinergic fibers are found to project from the hypothalamus to subregions of the hippocampus, septum, amygdala, and brainstem areas, where AVP serves as a neurotransmitter/neuromodulator via AVPR1a and AVPR1b receptors that are widely distributed (Surget and Belzung, 2008). AVP works through AVPR1b on pituitary corticotropes and the AVPR1b seems to be more reactive in depression (Dinan et al., 2004). In contrast, a major SNP haplotype of the AVPR1b has been found to protect against recurrent MDD (van West et al., 2004), while also evidence was found for the involvement of SNPs of AVPR1b in childhood-onset mood disorders, particularly in females (Dempster et al., 2007). These observations support the possibility of a direct involvement of AVP in the pathogenesis of depression, at least in some subjects. Moreover, particularly the magnocellular hypothalamic neurons release AVP from their dendrites and somata, subsequently diffusing through the brain’s extracellular fluid to act as neuromodulators on receptors at some distance from their site of release (Ludwig et al., 2005). Forth, AVP is also released into the brain with a circadian rhythm by neurons of the SCN, which shows significant changes in depression (see below). Once over-expressed and over-released, AVP may contribute to hyper-anxiety and depression-like behaviors, while AVP deficit, in turn, may cause signs of both diabetes insipidus, hypo-anxiety (Inder et al., 1997; Landgraf et al., 2007; Mlynarik et al., 2007; Iovino et al., 2018) and disturbed rhythmicity (Zhou et al., 2001; Wu et al., 2017).

As mentioned before, a multiple imbalance of receptor genes involved in the regulation of the HPA axis activity has been proposed in depression (Wang et al., 2008), in which the increased AVPR1a suggests a role of enhanced somato-dendritic AVP release in the PVN (Surget and Belzung, 2008). In addition, circulating AVP from the SON may induce ACTH release from the pituitary (Gispen-de Wied et al., 1992). Transient activation of the HPA axis following a single exposure to a stressor may induce delayed and long-lasting hyperproduction, hyperstorage, and hypersecretion of AVP, e.g. from hypothalamic CRH neurons, which result in hyperresponsiveness of the HPA axis to subsequent stimuli (Schmidt et al., 1995, 1996). The sensitization of neuronal processes is proposed to be an important feature in promoting depressive-like states. It was suggested that with each stressor experience and with each successive episode of depression, neuronal sensitization becomes more pronounced, and hence the stressor severity necessary to elicit the neurochemical changes (and thus to induce a depressive episode) becomes progressively smaller. This is in line with clinical observations that the relation between life-events and recurrences of depressive episodes is less clear in those patients who have highly recurrent MDD (Ten H ave et al., 2018). It is also important to note that, whereas in acute stress CRH is the main cause of increased ACTH release, animal experiments show that in chronic stress there is a switch from CRH to AVP stimulation of ACTH release (Scott and Dinan, 1998). Since depression is a chronic disorder, the AVP-driven HPA hyperactivity in depression is receiving more and more attention (Meynen et al., 2006). In case of chronic depression, AVP is proposed to be persistently increased within CRH neurons, so that even minor day-to-day annoyances might trigger excessive CRH/AVP release. This, in turn, would favor the presentation of dysphoric symptoms, and might even be a factor responsible for triggering MDD and dysthymia (Griffiths et al., 2000). The number of CRH and AVP-colocalizing neurons is indeed increased in the human PVN in depression and during the course of aging, at least in males (Bao and Swaab, 2007; Raadsheer et al., 1993, 1994b).

Feedback of corticosteroids takes place on the PVN, SON and SCN. Following different types of corticosteroid treatment in different disorders or during the presence of high levels of endogenous corticosteroids produced by a tumor, we found - in postmortem tissue - not only that CRH-expressing neurons are strongly down-regulated, but also that AVP expression in the SON and PVN is strongly decreased. On the other hand, OXT neurons were not affected. Therefore, in the human brain, the negative-feedback of corticosteroids is acting selectively on CRH cells and cells that (co-)express AVP but not on OXT cells. A glucocorticoid-induced suppression of AVP-synthesis has been proposed to occur at the posttranscriptional level (Erick et al., 1998, 2002). In the human SCN we found a diminished AVP mRNA following administration of corticosteroids (Liu et al., 2006a), which may be one explanation for the disturbed circadian rhythms in depression.

In the PVN of mood disorder patients, the number of AVP and OXT expressing neurons is increased (Purba et al., 1996). Using radioactive in situ hybridization, our group determined the amount of AVP mRNA in the PVN and SON in formalin-fixed, paraffin-embedded archival postmortem brain tissues of depressed subjects and their controls. In the SON, a 60% increase of AVP mRNA expression was found in depressed subjects but AVP mRNA expression was only significantly increased in both the SON and the PVN in the melancholic subgroup (Meynen et al., 2006). Enhanced AVP mRNA production in the SON of depressed patients (Meynen et al., 2006) leads to increased plasma levels of AVP (van Londen et al., 1997, 1998b; van Londen et al., 2001) that are also reported to be related to an enhanced suicide risk in depression (Inder et al., 1997), as well as to an anxious-retarded type of depression (de Winter et al., 2003; Goekeop et al., 2006). It has also been proposed that AVP may not only be important in mediating psychomotor retardation but also in affecting memory processes in depressed patients, possibly by altering arousal and attention (Van Londen et al., 1998a; van Londen et al., 1998b). The possibility that circulating AVP may also induce symptoms of depression is supported by the case-story of a man displaying chronically elevated plasma AVP levels due to AVP secretion by an olfactory neuroblastoma, which induced his first episode of MDD. Depressive symptoms improved markedly after surgical resection of the tumor and subsequent normalization of plasma AVP levels. In this patient the HPA axis was suppressed (Muller et al., 2000), indicating a primary role of AVP in the pathogenesis of depression.

In addition, in depression and suicide, alterations in centrally released AVP from the PVN may play a role, since immunoactive AVP was elevated in the dorsomedial prefrontal cortex and reduced in the dorsal vagal complex (Merali et al., 2006).
partly, the reason why there were opposing effects of sex hormones on this system: androgens inhibit and estrogens stimulate the release of ACTH and glucocorticoid secretion and thus diminish the neuroendocrine system that is involved in the regulation of stress responses (Smith et al., 2010), the attenuation of fear and of the stress response (Quirin et al., 2011), and the modulation of the symptoms of psychiatric disorders such as MDD and bipolar disorder (BD) (Cochran et al., 2013). Since the observations of the social and/or clinical effects of OXT have been generally performed by intranasal OXT administration, the belief that all effects of intranasal OXT can be explained by a direct OXT action on brain systems has been challenged (Leng and Ludwig, 2016).

The literature tends to remain equivocal on the direction of OXT changes in the circulation in depression. For instance, both enhanced (Heinrichs and Domes, 2008; Turan et al., 2013) and weakened (Ozsoy et al., 2009) serum OXT levels have been reported in mood disorders. These considerations rendered it crucial to do postmortem brain research on the OXT system in the brain in clinically and neuropsychologically well-characterized patients with mood disorders. Activation of OXT neurons has indeed been found in depression and may be related to decreased appetite and weight loss in this disease, due to the central effects of this neuropeptide as a satiety hormone (Gimpl and Fahrenholz, 2001; Meynen et al., 2007; Purba et al., 1996; Dai et al., 2017). Enhanced OXT production in the PVN was indeed found in postmortem material of melancholic depressed patients (Meynen et al., 2007). There is, in addition, an interesting diurnal variation in the HPA axis and depression. For instance, both enhanced (Richard and Zingg, 1990) and down-regulated by testosterone via its effect on the hypothalamus and has reciprocal connections with the limbic system, the aminergic system, the cholinergic system and the CRH neurons. Orexin stimulates CRH neurons (Lu et al., 2017). Recently, we have observed that the amount of orexin-ir neurons was significantly increased in female but not in male depression patients. In addition, hypothalamic orexin showed a clear diurnal fluctuation, which was absent in depression. Moreover, male depressive patients who had committed suicide showed significantly increased orexin-receptor-2-mRNA expression in the anterior cingulate cortex (Lu et al., 2017). These data showed a clear sex-related change in the hypothalamic orexin-ir in depression. In summary, these observations support the concept that the HPA axis holds a prominent position in a network of stress- (and reward-) related neurotransmitter and neuromodulator systems, all of which are also crucially involved in depression.

**Sex difference in the HPA axis and depression**

The sex difference found in depression might provide additional support for the CRH-hypothesis of depression. Since MDD is twice as prevalent in women of reproductive age as in men, organizing and/or activating effects of sex hormones, directly or indirectly on the HPA axis, are proposed as risk factors for depression. The possible importance of fluctuating levels of sex hormones as a risk factor for depression is underlined by the higher prevalence of premenstrual depression, antepartum or postpartum depression, and depression during the transition to menopause (Bao et al., 2004, 2012). Studies in rodents have found that the female brain’s innate strategy to handle stress differs from that of the male brain (Ter Horst et al., 2009). In addition, organizing effects of estrogen-like compounds during fetal life may also be responsible for a higher prevalence of mood disorders, as appeared in children exposed in utero to diethylstilbestrol (Meyer-Bahlburg and Ehnhardt, 1987). Furthermore, age-related sex differences have been found in CRH-expressing neurons in the human hypothalamic PVN, which illustrates a relationship between sex hormones and CRH. First, from the age of 24 years onward, men had significantly more CRH-expressing neurons than women, while in the second place there was a significant age-related increase of CRH-expressing neurons in men, but not in women (Bao and Swaab, 2007). It is of interest to note here that AVP neurons in the hypothalamic SON, which is the major source for circulating AVP, showed the opposite pattern. These neurons were only activated during the course of aging in women, and not in men (Ishimina et al., 1999). Moreover, an abnormal hormone status, induced by castration because of prostate cancer, ovariectomy or a sex hormone-producing tumor, was accompanied by changes in the number of CRH-expressing neurons in the human brain (Bao and Swaab, 2007).

It should be noted that sex hormones can also be synthesized locally in the brain as ‘neurosteroids’ (Qi et al., 2017), which may alter mood disorders and may interact with circulating sex hormones by as-yet unknown mechanisms. Sex hormones act by binding to sex hormone receptors that are expressed by CRH neurons in the hypothalamus and by corticotropes in the adenohypophysis (Bao et al., 2005, 2006; Pereira-Lima et al., 2004; Schelthauer et al., 2008; Stefanaeu et al., 1994). We have found co-localization of CRH and sex hormone receptors, indicating a direct effect of sex hormones on CRH neurons. Both nuclear ERα (Bao et al., 2005) and nuclear AR (Bao et al., 2006) were present in CRH expressing neurons in the human hypothalamic PVN. In addition, there was a significantly positive correlation between the increased number of CRH-expressing neurons containing nuclear ERα and the increased number of CRH neurons in mood disorders, both in males and females (Bao et al., 2005). The human CRH gene promoter contains 5 perfect, half-palindromic estrogen-responsive elements (EREs) (Vamvakopoulos and Chrousos, 1993), and animal studies have shown that estrogens stimulate CRH expression (Lund et al., 2004). We have also identified an androgen-responsive element (ARE) in the CRH gene promoter region, but that appeared to initiate a repressing effect of AR on CRH transcription (Bao et al., 2006), which is in agreement with an animal study showing that androgens inhibit CRH production (Lund et al., 2004). Interestingly, the human OXT gene promoter was also found to be up-regulated by estrogens when ER was present (Richard and Zingg, 1990) and down-regulated by testosterone via its combination with nuclear AR (Dai et al., 2017). The changes in the orexin system in depression were also sexually dimorphic. The number of orexin expressing neurons was only significantly increased in females, while male depressive patients who had committed suicide showed significantly increased orexin-receptor-2-mRNA expression in the anterior cingulate cortex (Lu et al., 2017). A change in the AVP level in depression in the biological clock, the SCN, was only present in female- and not in male depression patients (Wu et al., 2017). Sex plays, in addition, an important role in determining whether functional genetic variation in MR is beneficial or detrimental in the etiology of depression following childhood maltreatment (Vinkers et al., 2015).
Thus, there are sex differences in in stress systems that may be a basis for the sex difference in the prevalence of depression. Whether they are due to organizing or activating/inhibiting effects of sex hormones on these neuropeptide stress systems should be further investigated.

Interaction between the HPA axis and the SCN

HPA activity is modulated by the hypothalamic SCN, the biological clock. The SCN is of interest in relation to depression for various reasons. Light is directly influencing the activity of the SCN, and light therapy is effective in depression. In addition, seasonal affective disorder (SAD) is more prevalent in the northern states of the US than in southern states (Miller, 2005). Moreover, the symptoms of depression order (SAD) is more prevalent in the northern states of the US than in the southern states (Miller, 2005). Moreover, the symptoms of depression

![Schematic illustration of some of the key mechanisms that may cause a mood disorder by impaired input of neurotransmitters (monoamines and amino acids) and/or neuropeptides (arginine vasopressin (AVP), oxytocin (OXT)) on the hypothalamo-paraventricular nucleus (PVN) causes a chronic rise in CRH and cortisol levels in depression, which causes mood changes through their action on the brain. The hyperactivity of the HPA axis may be due to a multitude of risk factors such as genetic polymorphisms, development sequelae, and environmental factors. A decreased amount of AVP mRNA of the SCN was found in depression, which seems to be the basis of the impaired circadian regulation of the HPA system in depression and a decreased inhibition of CRH neurons. Arrow: stimulation; Bar with ball-head: inhibition. The thickness of the lines indicates the strength of the effects. ACTH, adrenocorticotropic hormone. Modified from Fig. 1 of (Bao et al., 2012).

![Schematic diagram of the human SCN showing the interactions between the hypothalamus, pituitary, and adrenal gland. The diagram illustrates the key mechanisms that may cause a mood disorder by impaired input of neurotransmitters (monoamines and amino acids) and/or neuropeptides. The SCN is involved in the regulation of cortisol levels and mood changes.](image-url)
patients, and may increase during the course of the disease. This may contribute to the circadian disorders in depression and be the basis for the efficacy of melatonin or melatonin receptor agonists in depression (Wu et al., 2013). It should be noted that corticosteroids inhibit SCN function (Liu et al., 2006a), which also indicates a close interaction between the SCN and the HPA activity. Light therapy is effective not only in SAD but also for MDD, while - as an adjutant to conventional antidepressants in MDD patients, or lithium in BD patients - morning light hastens and potentiates the antidepressant response (Wirz-Justice et al., 2005). We propose, therefore, that light therapy may not only reset the SCN activity in depression, but also diminish CRH activity in the PVN.

Conclusions

This review focused on the molecular neuropathology of mood disorders in the hypothalamus, and elucidated in particular the role of the HPA axis, and its interaction with monoamines, glutamate and GABA, neuropeptides, and an other hypothalamic nuclei, i.e. the SCN, in the pathogenesis of mood disorders (Fig. 1). All these changes are based upon variable alterations in genetic background, developmental history, sex, and environmental stressors. One may hope that in the future these data will allow a better prediction for the vulnerable neurobiological system in an individual depressed patient, and that this will lead, ultimately, to an optimal tailor-made anti-depressive therapy.

Conflicts of interest

The Authors declare no conflict of interest.

Acknowledgements

Prof. Ai-Min Bao was supported by the National Key Research and Development Program of China (2016YFC1306700), the National Natural Science Foundation of China (91322102). Prof. Dick Swaab was supported by Programme of Introducing Talents of Discipline to Universities of China (B13026) and Stichting Vrienden van het Herseninstituut.

References

Aihara, M., Ida, I., Yuuki, N., Oshima, A., Kumano, H., Takahashi, K., Fukuda, M., Orieuchi, N., Endo, K., Matsuda, H., Mikuni, M., 2007. HPA axis dysfunction in unmediated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res. 155, 245–256.

Bao, A.M., Swaab, D.F., 2007. Gender difference in age-related number of corticotropin-releasing hormone-expressing neurons in the human hypothalamic paraventricular nucleus and the role of sex hormones. Neuroendocrinology 85, 27–36.

Bao, A.M., Ji, Y.F., Van Someren, E.J., Swaab, D.F., Zhou, J.N., 2004. Diurnal rhythms of free estradiol and cortisol during the normal menstrual cycle in women with major depression. Horm. Behav. 45, 93–102.

Bao, A.M., Hestiantoro, A., Van Someren, E.J., Swaab, D.F., Zhou, J.N., 2005. Immunohistochemical localization of oxytocin receptors in human brain. Neuroscience 253, 155–164.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.

Benedetti, S., 2015. Chronobiology of bipolar disorder: therapeutic implication. Curr. Pharm. Rep. 17, 606.
O’Riabhil, S., Colmers, W.F., Elmqquist, J.K., Tecott, L.H., 2007. Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. J. Neurosci. 27, 6956–6964.

Henter, I.D., De Souza, R.T., Zarate Jr., C.A., 2018. Glutamatergic modulators in depression. Biol. Psychiatry 84, 685–691.

Herman, J.P., Mueller, N.K., Figueiredo, H., 2004. Role of GABA and glutamate circuitry in hypothalamic-pituitary-adrenocortical stress integration. Ann. N. Y. Acad. Sci. 1018, 35–45.

Heuser, R., Binette, G., Detting, M., Schweiger, U., Gothard, I., Schmidte, J., Lammers, C.H., Nemeroff, C.B., Holbofer, F., 1998. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress. Anxiety 8, 71–79.

Hirschfeld, R.M., 2012. The epidemiology of depression and the evolution of treatment. J. Clin. Psychiatry 73 (Suppl. 1), 5–9.

Hofman, M.A., Swaab, D.F., 1992. Seasonal changes in the suprachiasmatic nucleus of man. Neurosci. Lett. 139(1), 17–20.

Hofman, M.A., Swaab, D.F., 1993. Diurnal and seasonal rhythms of neuronal activity in the suprachiasmatic nucleus of humans. J. Biol. Rhythms 8, 283–295.

Holbofer, F., 1988. Implications of altered limbic-hypothalamic-pituitary-adrenocortical (HPA)-axis function for neurobiology of depression. Acta Psychiatr. Scand. Suppl. 341, 72–111.

Holbofer, F., 2001. Stress, hypercortisolism and corticotropin receptors in depression: implications for therapy. J. Affect. Dis. 62, 77–91.

Holbofer, F., Spengler, D., Heuser, J., 1992. The role of corticotropin-releasing hormone in the pathogenesis of cushing’s disease, anorexia nervosa, alcoholism, affective disorders and progesterone Brain Res 93, 385–417.

Hou, D.T., Lombardo, K.A., Herringa, R.J., Bakshi, V.P., Roseboom, P.H., Kalin, N.H., 2005. Regulation of activity-dependent dendritic vasopressin release from rat supraoptic neurons. J. Physiol. 564, 515–522.

Lund, T.D., Munson, D.J., Haldy, M.E., Handa, R.J., 2004. Androgen inhibits, while oestrogen enhances, response of neuropeptide neurones in the paraventricular nucleus of the hypothalamus. J. Neuroendocrinol. 16, 272–278.

Mali, G.S., Outhred, T., 2016. Therapeutic mechanisms of lithium in bipolar disorder: recent advances and current understanding. CNS Drugs 30, 931–949.

Mccarthy, M.J., Wei, H., Marony, Z., Davtian, R.M., Mephisto, D.L., Cohen, B.M., Welch, D.K., 2013. Genetic and clinical factors predict lithium’s effects on P2R2 gene expression in cells from bipolar disorder patients. Transl. Psychiatry 3, e318.

Meewisse, M.L., Reitsma, J.B., De Vries, G.J., Gersons, B.P., Olf, M., 2007. Cortisol and posttraumatic stress disorder in adults: systematic review and meta-analysis. Br. J. Psychiatry 191, 387–392.

Menezes, I.C, Von Werne Baes, C., Lacchini, R., Jurema, M.F., 2018. Genetic biomarkers for differential diagnosis of major depressive disorder and bipolar disorder: a systematic review and meta-analysis. Brain Res.

Merali, Z., Kent, P., Du, L., Hedna, P., Palkovits, M., Faludi, G., Poulter, M.O., Bedard, T., Anisman, H., 2006. Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neurelinin B alterations in stress-relevant brain regions of rats with forced swimming-induced depression. J. Neurosci. 26, 427–447.

Meyer-Bahlburg, H.F., Ehrhardt, A.A., 1987. A Prenatal-Hormone Hypothesis for Depression in Adults With a History of Fetal DES Exposure. Hormones and Depression. Raven Press, New York, USA.

Meyen, G., Unnebua, U.A., Hofman, M.A., Swaab, D.F., Hoogendijk, W.J., 2006. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: a preliminary report. Biol. Psychiatry 60, 192–196.

Meyen, G., Unnebua, U.A., Hofman, M.A., Swaab, D.F., Hoogendijk, W.J., 2007. Hypothalamic oxytocin mRNA expression and melancholic depression. Mol. Psychiatry 12, 118–119.

Miller, A.L., 2005. Epidemiology, etiology, and natural treatment of seasonal affective disorder. Alern. Med. Rev. 10, 5–13.

Mlynarik, M., Zelen, D., Bagdy, G., Maga, G.B., Jezova, D., 2007. Signs of attenuated depression-like behavior in vasopressin deficient brattleboro rats. Horm. Behav. 51, 395–405.

Morris, M.C., Compas, B.E., Garner, J., 2012. Relations among posttraumatic stress disorder, comorbid major depression, and HPA function: a systematic review and meta-analysis. Clin. Psychol. Rev. 32, 301–315.

Mullas, L., Landgraf, R., Kohn, M.E., 2000. Vasopressin, major depression, and hypothalamic-pituitary-adrenocortical desensitization. Biol. Psychiatry 48, 330–333.

Oliva, B., Martinho, V., Carvalho, V., Magalhaes, F., Rocha, K., Ayres, C., Teixeira, S., Nunes, M., Bastos, V.H., Pinto, G.R., 2018. Genetic polymorphisms associated with circadian rhythm dysregulation provide new perspectives on bipolar disorder. Bipolar Disord.

Oni-Owusu, P., James, A., Crane, J., Scrogin, K.E., 2005. 5-hydroxytryptamine 1A receptors in the paraventricular nucleus of the hypothalamic mediobase hypothalamic and adrenergic corticotropin hormone release and some behavioral components of the serotonin syndrome. J. Pharmacol. Exp. Ther. 315, 1324–1330.

Oswald, L.M., Wong, D.F., Mcmaul, Z., Zhou, Y., Kuwabara, H., Choi, L., Brasic, J., Wand, G.S., 2005. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology 30, 821–832.

Osoy, S., Ebel, E., Kula, M., 2009. Serum oxytocin levels in patients with depression and the effects of gender and antidepressant treatment. Psychiatry Res 169, 249–252.

Panayotocopoulou, M.T., Malidelis, Y., Van Heerikhuize, J., Unmehopa, U.A., Hofman, M.A., Swaab, D.F., Hoogendijk, W.J., 2006. Hypothalamic vasopressin mRNA expression and melancholic depression. Mol. Psychiatry 12, 118–119.

Price, J.L., Drevets, W.C., 2012. Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 16, 61–71.

Pruessner, J.C., Champagne, F., Meaney, M.J., Dagher, A., 2006. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]clonidine. J. Neurosci. 24, 3825–2831.

Purba, J.S., Hoogendijk, W.J., Hofman, M.A., Swaab, D.F., 1996. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 53, 137–143.

Qi, X.R., Kamphuis, W., Wang, S., Wang, Q., Lucasen, P.J., Zhou, J.N., Swaab, D.F., 2013. Aberrant stress hormone receptor balance in the human prefrontal cortex and hypothalamic paraventricular nucleus of depressed patients. Psychoneuroendocrinology 38, 863–870.
Qi, X.R., Zhao, J., Liu, J., Fang, H., Swaab, D.F., Zhou, J.N., 2015. Abnormal retinoid and TrkB signaling in the prefrontal cortex in mood disorders. Cereb. Cortex 25, 75–83.

Qi, X.R., Luchetti, S., Verwer, R.W.H., Sluiter, A.A., Mason, M.R.J., Zhou, J.N., Swaab, D.F., 2017. Alterations in the steroid biosynthetic pathways in the human prefrontal cortex in mood disorders: a post-mortem study. Brain Pathol.

Quinn, M., Kuhl, J., Dusing, R., 2011. Oxytocin buffers cortisol responses to stress in individuals with impaired emotion regulation abilities. Psychoneuroendocrinology 36, 898–904.

Raadsheer, F.C., Sluiter, A.A., Ravid, R., Tilders, F.J., Swaab, D.F., 1993. Localization of corticotropin-releasing hormone (CRH) neurons in the paraventricular nucleus of the human hypothalamus: Age-dependent colocalization with vasopressin. Brain Res. 615, 59–62.

Raadsheer, F.C., Hoogendijk, W.J., Stijm, F.C., Tilders, F.J., Swaab, D.F., 1994a. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60, 436–444.

Raadsheer, F.C., Tilders, F.J., Swaab, D.F., 1994b. Similar age related increase of vasopressin colocalization in paraventricular corticotropin-releasing hormone containing cells in controls and Alzheimer patients. J. Neuroendocrinol. 6, 131–133.

Raadsheer, F.C., Van Heerikhuize, J.J., Lucassen, P.J., Hoogendijk, W.J., Tilders, F.J., Swaab, D.F., 1995. Corticotropin-releasing hormone mRNA levels in the paraventricular nuc leus of patients with Alzheimer’s disease and depression. Am. J. Psychiatry 152, 1372–1376.

Richard, S., Zingg, H.H., 1990. The human oxytocin gene promoter is regulated by estrogen. J. Biol. Chem. 265, 6098–6103.

Rube, H.G., Mason, N.S., Schene, A.H., 2007. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12, 331–350.

Scheithauer, B.W., Kovacs, K., Zorludemir, S., Lloyd, R.V., Erdogan, S., Slezak, J., 2008. Immunoexpression of androgen receptor in the nontumorous pituitary and in adenomas. Endocr Pathol 19, 27–33.

Schmidt, E.D., Binnekade, R., Janszen, A.W., Tilders, F.J., 1996. Short stressor induced vasopressin colocalization in paraventricular corticotropin-releasing hormone containing cells in controls and Alzheimer patients. J. Neuroendocrinol. 6, 131–133.

Schmidt, E.D., Van Heerikhuize, J.J., Lucassen, P.J., Hoogendijk, W.J., Tilders, F.J., Swaab, D.F., 1995. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer’s disease and depression. Am. J. Psychiatry 152, 1372–1376.

Shi, J., Wittke-Thompson, J.K., Badner, J.A., Hattori, E., Potash, J.B., Willour, V.L., Yang, X., De, M., Ke, G., Smith, T., 2006. Genome-wide association of CRH receptor 1-knockout mice. Eur. J. Neurosci. 24, 2280–2288.

Shi, J., Wittke-Thompson, J.K., Badner, J.A., Hattori, E., Potash, J.B., Willour, V.L., Yang, X., De, M., Ke, G., Smith, T., 2006. Genome-wide association of CRH receptor 1-knockout mice. Eur. J. Neurosci. 24, 2280–2288.

Sigurdsson, B., Palsson, S.P., Arvadsson, O., Olafsdottir, M., Johannsson, M., 2014. Saliva testosterone and cortisol in male depressive syndrome, a community study. J. Psychosom. Res. 76, 595–603.

Smith, A.S., Agmo, A., Birnie, A.K., French, J.A., 2010. Manipulation of the oxytocin system alters social behavior and attraction in pair-bonding primates, Callithrix penicillata. Horm. Behav. 57, 255–262.

Sprengel, S.R., Zorrilla, E.P., 2017. Don’t stress about CRF: assessing the translational failures of CRF1 antagonists. Psychopharmacology (Berl) 234, 1467–1481.

Stefaneana, L., Kovacs, K., Horvath, E., Lloyd, R.V., Buchfelder, M., Fahibus, R., Smyth, M., 1994. In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophyseal cells and pituitary adenomas. J. Clin. Endocrinol. Metab. 78, 83–88.

Strickland, P.L., Deakin, J.F., Percival, C., Dixon, J., Gater, R.A., Goldberg, D.P., 2002. Bio-social origins of depression in the community. Interactions between social adversity and genetic risk factors. Br. J. Psychiatry 180, 168–173.

Surget, A., Belzu, G., 2008. Involvement of vasopressin in a syndrome produced by diverse noxious agents. J. Neuroendocrinol. 8, 703–712.

Tillersen, A., Belzung, C., 2008. Involvement of vasopressin in a syndrome produced by diverse noxious agents. J. Neuroendocrinol. 8, 703–712.

Vinkers, C.H., Joels, M., Milaneschi, Y., Gerritsen, L., Kahn, R.S., Penninx, B.W., Boks, P.M., 2015. Mineralocorticoid receptor haplotypes sex dependently moderate depression susceptibility following childhood maltreatment. Psychoneuroendocrinology 54, 90–102.

Wang, S.S., Kamphuis, W., Huitinga, I., Zhou, J.N., Swaab, D.F., 2008. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol. Psychiatry 13 (786-99), 741.

Wang, Q., Joels, M., Swaab, D.F., Lucassen, P.J., 2012. Hippocampal CR expression is increased in elderly depressed females. Neuropharmacology 62, 527–533.

Wang, Q., Verweij, E.W., Krugers, H.J., Joels, M., Swaab, D.F., Lucassen, P.J., 2014. Distribution of the glucocorticoid receptor in the human amygdala. Changes in mood disorder patients. Brain Struct. Funct. 219, 1615–1626.

Waselius, M., Valentino, R.J., Van Bockstaele, E.J., 2011. Collateralized dorsal raphe nucleus projections: a mechanism for the integration of diverse functions during stress. J. Chem. Neuroanat. 41, 266–260.

Witsoe, A.M., Balesar, R., Rao, A.M., 2013. Unaltered histaminergic system in depression: a postmortem study. J. Affect. Disord. 146, 220–223.

Witsoe, A.M., Balesar, R., Rao, A.M., 2013. Unaltered histaminergic system in depression: a postmortem study. J. Affect. Disord. 146, 220–223.

Shi, J., Witte-Thompson, J.K., Badner, J.A., Hattori, E., Potash, J.B., Willour, V.L., Mcmahon, F.J., Gershon, E.S., Liu, C., 2008. Clock genes may influence bipolar disorder susceptibility and dysfunctional circadian rhythm. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1047–1055.

Sjogren, B., Palsson, S.P., Arvadsson, O., Olafsdottir, M., Johannsson, M., 2014. Saliva testosterone and cortisol in male depressive syndrome, a community study. J. Psychosom. Res. 76, 595–603.

Smith, A.S., Agmo, A., Birnie, A.K., French, J.A., 2010. Manipulation of the oxytocin system alters social behavior and attraction in pair-bonding primates, Callithrix penicillata. Horm. Behav. 57, 255–262.

Sprengel, S.R., Zorrilla, E.P., 2017. Don’t stress about CRF: assessing the translational failures of CRF1 antagonists. Psychopharmacology (Berl) 234, 1467–1481.

Stefaneana, L., Kovacs, K., Horvath, E., Lloyd, R.V., Buchfelder, M., Fahibus, R., Smyth, M., 1994. In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophyseal cells and pituitary adenomas. J. Clin. Endocrinol. Metab. 78, 83–88.

Strickland, P.L., Deakin, J.F., Percival, C., Dixon, J., Gater, R.A., Goldberg, D.P., 2002. Bio-social origins of depression in the community. Interactions between social adversity and genetic risk factors. Br. J. Psychiatry 180, 168–173.

Surget, A., Belzu, G., 2008. Involvement of vasopressin in affective disorders. Eur. J. Pharmacol. 583, 340–349.

Swaab, D.F., 2003. The human hypothalamus. Basic and clinical aspects. Part I: nuclei of the hypothalamus. In: AMINOF, M.J., F. B, SWAAB, D.F. (Eds.), Handbook of Clinical Neurology. Elsevier, Amsterdam.

Swaab, D.F., 2004. The human hypothalamus. Basic and clinical aspects. Part II: neuro-pathology of the hypothalamus and adjacent brain structures. In: AMINOF, M.J., F. B, SWAAB, D.F. (Eds.), Handbook of Clinical Neurology. Elsevier, Amsterdam.